Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2509-2513

  McKee, Trevor D ^a,b   Grandi, Paola ^a   Mok, Wilson ^a,c   Alexandrakis, George ^a   Insin, Numpon ^b   Zimmer, John P ^b   Bawendi, Moungi G ^b   Boucher, Yves ^a   Breakefield, Xandra O ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; FIBRILLAR COLLAGEN; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; COLLAGEN METABOLISM; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HERPES SIMPLEX VIRUS; HERPESVIRUS VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIRUS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; COLLAGENASES; FIBRILLAR COLLAGENS; GENE EXPRESSION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; HUMANS; MELANOMA; MICE; MICE, SCID; ONCOLYTIC VIROTHERAPY; TISSUE DISTRIBUTION; VIRION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645066093     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2242     Document Type: Article

References (20)

1. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005;12:141-61.
2. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
3. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001;61:5336-9.
4. Lee CT, Park KH, Yanagisawa K, et al. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 2004;64:6660-5.
5. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
6. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 2001;12:1323-32.
7. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
8. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001;98:4628-33.
9. Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003;9:796-800.
10. Chiocca EA, Choi BB, Cai WZ, et al. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol 1990;2:739-46.
11. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997;8:2057-68.
12. Samaniego LA, Webb AL, DeLuca NA. Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995;69:5705-15.
13. Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc Natl Acad Sci U S A 2000;97:8146-50.
14. Chan Y, Zimmer JP, Stroh M, et al. Incorporation of luminescent nanocrystals into monodisperse core-shell silica microspheres. Adv Mater (FRG) 2004;16:2092-7.
15. Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res 2001;61:1805-9.
16. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001;264:169-84.
17. Jia W, Zhou Q. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. Curr Gene Ther 2005;5:133-42.
18. Currier MA, Adams LC, Mahller YY, Cripe TP. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Curr Gene Ther 2005;12:407-16.
19. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-98.
20. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 2004; 64:1687-94.